



IPSOGEN
CANCER PROFILER

PRESS RELEASE

IPSOGEN receives an offer from QIAGEN to fully acquire IPSOGEN and enters into exclusive negotiations

Marseille, France, June 15, 2011 – IPSOGEN S.A. (Alternext: ALIPS, ISIN: FR0010626028), Cancer Profiler, who develops, manufactures and commercializes molecular diagnostic assays for leukemia and breast cancer announces today that QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) has made an offer and entered into exclusive negotiations to purchase a 47% initial stake in IPSOGEN S.A. and subsequently make a voluntary public offer to fully acquire the outstanding shares of IPSOGEN S.A.

IPSOGEN, which has approximately 70 employees at sites in France and the United States, reported 24% net sales growth in 2010 to €8.4 million (approximately \$12 million) from a group of more than 400 active customers around the world. More than 40% of net sales were reinvested during 2010 into R&D activities.

"IPSOGEN has created a portfolio of molecular assays that are advancing treatment standards for patients with blood cancers, and we are now moving forward in creating new products to support women with breast cancer," said Vincent Fert, Chief Executive Officer of IPSOGEN. *"In the event the transaction is completed and that IPSOGEN becomes part of QIAGEN as a global center of excellence, we believe our efforts would be accelerated and benefit from an industry-leading company and could offer even greater options to patients and healthcare providers around the world."*

"The acquisition of IPSOGEN would further expand our global leadership in molecular assays for profiling and personalized healthcare," said Peer Schatz, Chief Executive Officer of QIAGEN N.V. *"IPSOGEN's molecular cancer profiling and personalized healthcare assays are clear leaders in setting standards for the diagnosis and monitoring of many types of blood cancers as well as the selection and guidance of therapies. This portfolio would further increase our leading position in profiling assays, as well as in companion diagnostics for personalized healthcare, helping to improve the treatment of many diseases and addressing unmet medical needs."*

IPSOGEN has developed a significant expertise in blood and breast cancer molecular diagnostics

IPSOGEN is a pioneer in developing and marketing a range of cancer profiling and personalized healthcare diagnostics that help map diseases and guide the decisions of physicians and patients. These advanced diagnostics provide significant benefits, particularly to patients by improving standards of care as well as to healthcare payors by optimizing overall treatment costs. These tests also provide advantages to physicians by enabling them to personalize therapeutic strategies, while pharmaceutical companies can optimize development of new medicines to target patients most likely to benefit.

IPSOGEN's tests are based on the same PCR quantitative technology (polymerase chain reaction) as the one used by QIAGEN in many of its own assays. PCR technology allows for the detection and measurement of molecular abnormalities in cancerous cells in a very precise and highly sensitive way.



IPSOGEN
CANCER PROFILER

PRESS RELEASE

The approximately 80 tests in IPSOGEN's portfolio are divided into four assay families, with products designed for specific needs in terms of diagnosis, prognosis and monitoring:

- BCR-ABL (Chronic Myeloid Leukemia)
- JAK2 V617F (various myeloproliferative diseases)
- PML-RARA (Promyelocytic Leukemia)
- A group of several products for use with a range of rare forms of leukemia

The top-selling group involves molecular assays for the diagnosis and monitoring of mutations of JAK2 (Janus kinase 2), a protein believed to play a role in various blood cancers and a target of many biotechnology compounds in pharmaceutical R&D. IPSOGEN's JAK2 tests are currently being used as a qualitative assay to diagnose various myeloproliferative diseases, a group of conditions that cause blood cells to grow abnormally in the bone marrow. These tests also are increasingly used as a quantitative technology in monitoring therapy since any reduction in the mutant JAK2 could illustrate the efficacy of a treatment in patients.

IPSOGEN has a competitive advantage based on its exclusive licenses for JAK2. It has been strengthening intellectual property protection for this key biomarker while building up a group of more than 20 licensed partners around the world. In 2010, for example, the U.S. Patent and Trademark Office granted additional intellectual property claims to IPSOGEN for detecting and using the JAK2 V617F mutation for diagnostic purposes.

IPSOGEN also is developing the Genomic Grade test (GG), a multigene expression test that seeks to address unmet diagnostic needs for women with early invasive hormone-receptor positive breast cancer.

Transaction summary

A group of IPSOGEN shareholders comprised of members and censor of the Board of Directors, holding shares representing in aggregate approximately 47% of IPSOGEN share capital, have agreed to enter into exclusive negotiations with QIAGEN in respect of the proposed acquisition by QIAGEN of their shares in IPSOGEN at a price of € 12.90 per share. In addition, in the event a definitive purchase agreement is entered into and the acquisition consummated, QIAGEN would launch a process to acquire all remaining outstanding shares at € 12.90 per share. This price would represent a 72.5% premium over IPSOGEN's share price of € 7.48 on June 10, 2011. The total value to fully acquire IPSOGEN is valued at approximately € 70 million. The workers council of IPSOGEN is being consulted on the QIAGEN offer for its opinion.

All three managing cofounders – Vincent Fert (Chief Executive Officer), Stéphane Debono (Chief Operating Officer) and Fabienne Hermitte (R&D and Regulatory Affairs Senior Director) – would be staying with QIAGEN following the acquisition and contribute to the combined future development.

Shearman & Sterling LLP is acting as legal advisor to IPSOGEN in relation to this offer. Rothschild and Kempen & Co. are acting as financial advisors and Darrois Villey Maillot Brochier is acting as legal advisor to QIAGEN in relation to this offer.

About IPSOGEN



IPSOGEN
CANCER PROFILER

PRESS RELEASE

IPSOGEN, cancer profiler, develops and markets molecular diagnostic tests that help to map diseases and guide patients and oncologists' decisions along their therapeutic path.

With more than 80 tests already used routinely worldwide for the diagnosis, prognosis and follow up of thousands of patients with leukemia, IPSOGEN is now targeting breast cancer with the aim of providing currently inaccessible diagnostic information.

Strengthened by its scientific, clinical and technological partnerships, and by its multidisciplinary team in France and the USA, IPSOGEN intends to become a world leader in the molecular profiling of cancers, and to continue the development and promotion of best-in-class diagnostic references that have a significant impact on patients, medical professionals and society. The company is headquartered in Marseille, France, and has a subsidiary in the USA. For further information, visit www.ipsogen.com.

About QIAGEN

QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated bio-molecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics. QIAGEN employs nearly 3,600 people in over 30 locations worldwide. Further information about QIAGEN can be found at <http://www.qiagen.com/>.

Contacts

IPSOGEN

Pascale Boissel

CFO
Tel: + 33 (0)4 9129 3090
pascale.boissel@ipsogen.com

Vincent Fert

CEO
Tel: + 33 (0)4 9129 3090
fert@ipsogen.com

NewCap.

Financial communication
& Investor relations

Axelle Vuillermet & Pierre Laurent

Tel: + 33 (0)1 44 71 94 93
ipsogen@newcap.fr

ALIPS
LISTED
NYSE
ALTERNEXT